



April 3, 2023

To Whom It May Concern

Company: KYORIN Pharmaceutical Co., Ltd.
Representative: Yutaka Ogihara
Representative Director, President
(Security Code: 4569, TSE Prime.)
Contact: Yoshinori Tanifuji
Director, Corporate Planning
Telephone: 03-3525-4707

Notice of Absorption Type Merger of Wholly Owned Subsidiary KYORIN
Pharmaceutical Co., Ltd and Change of Trade Name

KYORIN Pharmaceutical Co., Ltd. (formerly known as KYORIN Holdings, Inc., “Company”) announced today that it has merged its wholly owned subsidiary KYORIN Pharmaceutical Co., Ltd. (“KYORIN”), the main business subsidiary of KYORIN Group (“Group”), and has changed its trade name to “KYORIN Pharmaceutical Co., Ltd.” on April 1, 2023.

In view of such rapid changes in the environment and the situation of the Group, the Group has renovated its structure in 2023, when the Company celebrate its 100th anniversary, to improve its business promotion function and management efficiency. The Company has shifted from a pure holding company structure to a business holding company structure through the reorganization of the Group by absorbing the KYORIN into KYORIN Holdings, Inc. and has changed its trade name to "KYORIN Pharmaceutical Co., Ltd.”.

Along with focusing our strength on the new drug business as the Group’s core business, it will comprehensively develop the generic drug business, infection-related business, and contract drug manufacturing business. The Group strives to make a leap forward for the next 100 years.

Post-Merger status

- (i) Trade name: KYORIN Pharmaceutical, Co., Ltd.
- (ii) Location: 6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JAPAN
- (iii) Representative: Representative Director, President and Chief Executive Officer, Yutaka Ogihara
- (iv) Main business: Manufacture, sale and purchases of prescription medicines
- (v) Capital stock: 700 million yen
- (vi) Fiscal year-end: March 31